Profile data is unavailable for this security.
About the company
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release alternatives to approved drugs. The Company’s principal business is the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidate, EP-104IAR, is designed to meet the unmet medical need and market demand for long-lasting pain relief for knee osteoarthritis (OA). The primary active ingredient of the EP-104 products consists of a solid core of fluticasone propionate (FP) coated with an outer layer of polyvinyl alcohol (PVA). Its lead product candidate is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms and is used corticosteroid with systemic safety record. EP-104 is in Phase Ib/IIa clinical development.
- Revenue in CAD (TTM)0.00
- Net income in CAD-41.80m
- Incorporated2012
- Employees29.00
- LocationEupraxia Pharmaceuticals Inc201-2067 Cadboro Bay Rd.VICTORIA V8R 5G4CanadaCAN
- Phone+1 (250) 590-3968
- Fax+1 (250) 590-2588
- Websitehttps://eupraxiapharma.com/home/default.aspx
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sernova Corp | 0.00 | -40.73m | 90.57m | -- | -- | 23.74 | -- | -- | -0.1343 | -0.1343 | 0.00 | 0.0126 | 0.00 | -- | -- | -- | -124.29 | -74.84 | -180.95 | -85.03 | -- | -- | -- | -- | -- | -- | 0.142 | -- | -- | -- | -59.69 | -- | -2.91 | -- |
| Arch Biopartners Inc | 1.85m | -1.95m | 106.53m | -- | -- | -- | -- | 57.68 | -0.0312 | -0.0312 | 0.0296 | -0.091 | 2.73 | -- | 4.38 | -- | -288.23 | -214.82 | -- | -- | -- | -- | -105.69 | -180.45 | -- | -3.94 | -- | -- | 105.63 | -- | -136.30 | -- | -- | -- |
| Biosyent Inc | 32.84m | 7.05m | 107.41m | 0.00 | 15.62 | 3.08 | 14.30 | 3.27 | 0.5856 | 0.5856 | 2.72 | 2.97 | 0.8341 | 1.23 | 10.80 | -- | 17.92 | 14.77 | 20.00 | 16.92 | 80.41 | 79.74 | 21.48 | 19.99 | 6.37 | -- | 0.0329 | 9.26 | 13.12 | 7.97 | 18.35 | 2.52 | -2.67 | -- |
| Oncolytics Biotech Inc | 0.00 | -28.21m | 112.38m | 29.00 | -- | 4.89 | -- | -- | -0.4027 | -0.4027 | 0.00 | 0.3046 | 0.00 | -- | -- | -- | -80.51 | -81.99 | -88.84 | -97.25 | -- | -- | -- | -- | -- | -- | 0.0468 | -- | -- | -- | -11.75 | -- | -40.52 | -- |
| Spectral Medical Inc | 1.74m | -17.93m | 134.54m | 29.00 | -- | -- | -- | 77.50 | -0.0643 | -0.0647 | 0.0062 | -0.0721 | 0.2507 | 3.23 | 2.19 | 59,862.07 | -258.89 | -109.65 | -18,581.35 | -175.35 | 37.85 | 63.74 | -1,032.89 | -445.72 | 0.3287 | -2.56 | -- | -- | -4.14 | -16.08 | -104.12 | -- | 31.53 | -- |
| Eupraxia Pharmaceuticals Inc | 0.00 | -41.80m | 138.24m | 29.00 | -- | 5.20 | -- | -- | -1.65 | -1.65 | 0.00 | 0.7495 | 0.00 | -- | -- | 0.00 | -122.29 | -127.84 | -185.74 | -935.99 | -- | -- | -- | -- | -- | -85.63 | 0.3455 | -- | -- | -- | -52.63 | -- | -7.69 | -- |
| NervGen Pharma Corp | 0.00 | -20.02m | 143.34m | 10.00 | -- | 7.65 | -- | -- | -0.3363 | -0.3363 | 0.00 | 0.2692 | 0.00 | -- | -- | -- | -78.68 | -121.15 | -138.24 | -180.20 | -- | -- | -- | -- | -- | -9.07 | 0.0092 | -- | -- | -- | -8.01 | -- | 2.20 | -- |
| Zentek Ltd | 33.61k | -11.98m | 149.48m | 27.00 | -- | 6.69 | -- | 4,447.40 | -0.1197 | -0.1197 | 0.0003 | 0.2228 | 0.0013 | 0.0796 | 0.0876 | 1,244.82 | -44.53 | -41.94 | -48.53 | -44.46 | -573.70 | -- | -35,636.60 | -12,771.31 | 4.27 | -- | 0.0538 | -- | -79.01 | -- | 54.52 | -- | 39.27 | -- |
| Medicenna Therapeutics Corp | 0.00 | -15.42m | 175.60m | 18.00 | -- | 8.82 | -- | -- | -0.2215 | -0.2215 | 0.00 | 0.2675 | 0.00 | -- | -- | -- | -50.19 | -48.65 | -56.66 | -54.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 55.49 | -- | -- | -- |
